Is Suven Life Sciences Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Suven Life Sciences Ltd (SUVEN.NS) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Suven Life Sciences Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Suven Life Sciences Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Suven Life Sciences Ltd?

Muslim investors may consider investing in Suven Life Sciences Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Suven Life Sciences Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Suven Life Sciences Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Suven Life Sciences Ltd updated?

The Shariah compliance status of Suven Life Sciences Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Suven Life Sciences Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Suven Life Sciences Ltd?

You can check the latest Shariah compliance status of Suven Life Sciences Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

SUVEN.NS Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 05, 2026

Report Source: 2026 3rd Quarter Report

Suven Life Sciences Ltd. Stock Analysis SUVEN.NS

India Health Care Small Cap Report: Q3, 2026

Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The firm's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).

Key Statistics of Suven Life Sciences Ltd (SUVEN.NS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

₹202.31₹217.00

Today's Open

₹206.55

Volume

541.88K

P/E Ratio (TTM)

52 Week Range

₹124.11₹299.99

Market Cap

56.11B

Avg. Volume

460.15K

Dividend Yield

Financial Metrics & Statements of Suven Life Sciences Ltd (SUVEN.NS)

FAQ's for Suven Life Sciences Ltd (SUVEN.NS)

According to Musaffa’s Shariah screening methodology, Suven Life Sciences Ltd (SUVEN.NS) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.